DCGI Grants Conditional Market Approval For Covishield and Covaxin

New-Delhi: The Drugs Controller General of India (DCGI) on Thursday granted conditional market approval for Covishield and Covaxin.

However, it is important to note that the market approval does not mean that the vaccines will be available in medical shops. People will have to buy Covishield and Covaxin from hospitals and clinics.

The vaccination data has to be submitted to DCGI every six months. This data will also be required to be updated on CoWIN app also.

Sources said the firms manufacturing Covid vaccines the Serum Institute of India (Covishield) and Bharat Biotech (Covaxin) will have to submit data of clinical trials that are underway as well as of vaccines to be supplied for programmatic setting.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) had on January 19 cleared the proposal to grant regular market approval to the two vaccines.

The price of Covishield and Covaxin is likely to be capped at Rs 275 per dose plus an additional service charge of Rs 150, say sources.

 

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.